Tom De Bruyn

Tom De Bruyn

Auto-generated profile, based on publicly available information

Tom De Bruyn

Drug Metabolism and Pharmacokinetics Genentech, Inc. South San Francisco California USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2013 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
TBTom De Bruyn
Tom De Bruyn
SCSagnik Chatterjee
Sagnik Chatterjee
SFSarinj Fattah
Sarinj Fattah
JKJanneke Keemink
Janneke Keemink
JNJohan Nicolaï
Johan Nicolaï
PAPieter Annaert
Pieter Annaert
The sandwich-cultured hepatocyte (SCH) model has become an invaluable in vitro tool for studying hepatic drug transport, metabolism, biliary excretion and toxicity. The relevant expression of many hepatocyte-specific functions together with the in vivo-like morphology favor SCHs over other preclinical models for evaluating hepatobiliary drug disposition and drug-induced hepatotoxicity. In this review, the authors highlight recommended procedures required for reproducibly culturing hepatocytes in sandwich configuration. It also provides an overview of the SCH model characteristics as a function of culture time. Lastly, the article presents a summary of the most prominent applications of the SCH model, including hepatic drug clearance prediction, drug-drug interaction potential and drug-induced hepatotoxicity. When human (cryopreserved) hepatocytes are used to establish sandwich cultures, the model appears particularly valuable to quantitatively investigate clinically relevant mechanisms related to in vivo hepatobiliary drug disposition and hepatotoxicity. Nonetheless, the SCH model would largely benefit from better insight into the fundamental cell signaling mechanisms that are critical for long-term in vitro maintenance of the hepatocytic phenotype. Studies systematically exploring improved cell culture conditions (e.g., co-cultures or extracellular matrix modifications), as well as in vitro work identifying key transcription factors involved in hepatocyte differentiation are currently emerging.

1 June 2013 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
TBTom De Bruyn
Tom De Bruyn
GWGerard Van Westen
Gerard Van Westen
AIAdriaan P. Ijzerman
Adriaan P. Ijzerman
BSBruno Stieger
Bruno Stieger
PWPeter de Witte
Peter de Witte
PAPieter P. Annaert
Pieter P. Annaert
Several recent studies show that inhibition of the hepatic transport proteins organic anion-transporting polypeptide 1B1 (OATP1B1) and 1B3 (OATP1B3) can result in clinically relevant drug-drug interactions (DDI). To avoid late-stage development drug failures due to OATP1B-mediated DDI, predictive in vitro and in silico methods should be implemented at an early stage of the drug candidate evaluation process. In the present study, we first developed a high-throughput in vitro transporter inhibition assay for the OATP1B subfamily. A total of 2000 compounds were tested as potential modulators of the uptake of the OATP1B substrate sodium fluorescein, in OATP1B1- or 1B3-transfected Chinese hamster ovary cells. At an equimolar substrate-inhibitor concentration of 10 µM, 212 and 139 molecules were identified as OATP1B1 and OATP1B3 inhibitors, respectively (minimum 50% inhibition). For 69 compounds, previously not identified as OATP1B inhibitors, concentration-dependent inhibition was also determined, yielding Ki values ranging from 0.06 to 6.5 µM. Based on these in vitro data, we subsequently developed a proteochemometrics-based in silico model, which predicted OATP1B inhibitors in the test group (20% of the dataset) with high specificity (86%) and sensitivity (78%). Moreover, several physicochemical compound properties and substructures related to OATP1B1/1B3 inhibition or inactivity were identified. Finally, model performance was prospectively verified with a set of 54 compounds not included in the original dataset. This validation indicated that 80 and 74% of the compounds were correctly classified for OATP1B1 and OATP1B3 inhibition, respectively.

1 November 2011 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
TBTom De Bruyn
Tom De Bruyn
SFSarinj Fattah
Sarinj Fattah
BSBruno Stieger
Bruno Stieger
PAPatrick Augustijns
Patrick Augustijns
PAPieter Annaert
Pieter Annaert

1 July 2011 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
TBTom De Bruyn
Tom De Bruyn
ZYZhi-Wei Ye
Zhi-Wei Ye
APAnnelies Peeters
Annelies Peeters
JSJasminder Sahi
Jasminder Sahi
MBMyriam Baes
Myriam Baes
PAPieter Annaert
Pieter Annaert

1 June 2014 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
TBTom De Bruyn
Tom De Bruyn
WSWouter Sempels
Wouter Sempels
JSJan Snoeys
Jan Snoeys
NHNico Holmstock
Nico Holmstock
SCSagnik Chatterjee
Sagnik Chatterjee
PAPieter Annaert
Pieter Annaert

1 July 2018 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
TBTom De Bruyn
Tom De Bruyn
AUAyşe Ufuk
Ayşe Ufuk
CCCarina Cantrill
Carina Cantrill
RKRachel E. Kosa
Rachel E. Kosa
YBYi-An Bi
Yi-An Bi
JHJ. Brian Houston
J. Brian Houston
This work explores the utility of the cynomolgus monkey as a preclinical model to predict hepatic uptake clearance mediated by organic anion transporting polypeptide (OATP) transporters. Nine OATP substrates (rosuvastatin, pravastatin, repaglinide, fexofenadine, cerivastatin, telmisartan, pitavastatin, bosentan and valsartan) were investigated in plated cynomolgus monkey and human hepatocytes. Total uptake clearance and passive diffusion were measured in vitro from initial rates in the absence and presence of the OATP inhibitor rifamycin SV, respectively. Total uptake clearance values in plated hepatocytes ranged over three orders of magnitude in both species with a similar rank order and good agreement in the relative contribution of active transport to total uptake between cynomolgus monkey and human. In vivo hepatic clearance for these nine drugs was determined in cynomolgus monkey after intravenous dosing. Hepatic clearances showed a similar range to human parameters and good predictions from respective hepatocyte parameters (with 2.7 and 3.8-fold bias on average, respectively). The use of cross species empirical scaling factors (based on either dataset average or individual drug scaling factor from cynomolgus monkey data) improved prediction (less bias, better concordance) of human hepatic clearance from human hepatocyte data alone. In vitro intracellular binding in hepatocytes also correlated well between species. It is concluded that the minimal species differences observed for the current dataset between cynomolgus monkey and human hepatocyte uptake, both in vitro and in vivo, support future use of this preclinical model to delineate drug hepatic uptake and enable prediction of human in vivo intrinsic hepatic clearance.